舒更葡糖与新斯的明逆转神经肌肉阻滞的疗效与安全性比较:Cochrane系统评价与Meta分析
本Cochrane系统评价纳入41项随机临床试验共4206例成人患者,比较舒更葡糖与新斯的明逆转神经肌肉阻滞的效果。舒更葡糖从第二个颤搐恢复至四个成串刺激比值>0.9的时间为2.0分钟(2 mg.kg-1),新斯的明为12.9分钟(0.05 mg.kg-1),平均差10.2(95%CI 8.5-12.0)。舒更葡糖组复合不良事件风险显著更低(RR 0.60,95%CI 0.49-0.74),但严重不良事件风险无显著差异。
要点
- 舒更葡糖2 mg.kg-1逆转深度阻滞至TOF比值>0.9比新斯的明0.05 mg.kg-1快约10分钟
- 舒更葡糖组复合不良事件、心动过缓、术后恶心呕吐及残余麻痹征象均显著减少
核心结论
- 舒更葡糖逆转神经肌肉阻滞比新斯的明更迅速,且不良事件更少。
研究设计与样本
- Cochrane系统评价与Meta分析,纳入41项随机临床试验,共4206例成人患者。
主要发现
- 从第二个颤搐至TOF比值>0.9:舒更葡糖2 mg.kg-1为2.0分钟,新斯的明0.05 mg.kg-1为12.9分钟,MD 10.2(95%CI 8.5-12.0),I2=84%,10项研究,n=835,GRADE中等质量。
- 从PTC 1-5至TOF比值>0.9:舒更葡糖4 mg.kg-1为2.9分钟,新斯的明0.07 mg.kg-1为48.8分钟,MD 45.8(95%CI 39.4-52.2),I2=0%,2项研究,n=114,GRADE低质量。
- 复合不良事件:舒更葡糖组显著少于新斯的明组,RR 0.60(95%CI 0.49-0.74),I2=40%,28项研究,n=2298,NNT=8,GRADE中等质量。
- 心动过缓:RR 0.16(95%CI 0.07-0.34),n=1218,NNT=14,GRADE中等质量;术后恶心呕吐:RR 0.52(95%CI 0.28-0.97),n=389,NNT=16,GRADE低质量;术后残余麻痹总体征象:RR 0.40(95%CI 0.28-0.57),n=1474,NNT=13,GRADE中等质量。
- 严重不良事件:两组无显著差异,RR 0.54(95%CI 0.13-2.25),I2=0%,n=959,GRADE低质量。
关键数值与推荐
- 逆转从第二个颤搐至TOF比值>0.9:舒更葡糖2 mg.kg-1对比新斯的明0.05 mg.kg-1,MD 10.2(95%CI 8.5-12.0)。
- 逆转从PTC 1-5至TOF比值>0.9:舒更葡糖4 mg.kg-1对比新斯的明0.07 mg.kg-1,MD 45.8(95%CI 39.4-52.2)。
- 复合不良事件RR 0.60(95%CI 0.49-0.74),NNT=8;心动过缓RR 0.16(95%CI 0.07-0.34),NNT=14;术后恶心呕吐RR 0.52(95%CI 0.28-0.97),NNT=16;术后残余麻痹征象RR 0.40(95%CI 0.28-0.57),NNT=13。
- 严重不良事件RR 0.54(95%CI 0.13-2.25),无显著差异。
临床怎么用
- 在需要快速逆转神经肌肉阻滞的临床场景中,舒更葡糖较新斯的明能更快恢复TOF比值>0.9。
- 舒更葡糖可降低复合不良事件、心动过缓、术后恶心呕吐及残余麻痹征象的风险。
- 严重不良事件风险两组无显著差异,选择药物时需结合患者具体情况。
局限性
- 部分结局证据质量低(如PTC逆转、术后恶心呕吐、严重不良事件),研究间异质性在部分分析中较高(I2=84%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We compared the efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. Our outcomes were: recovery time from second twitch to train-of-four ratio > 0.9; recovery time from post-tetanic count 1-5 to train-of-four ratio > 0.9; and risk of composite adverse and serious adverse events. We searched for randomised clinical trials irrespective of publication status and date, blinding status, outcomes reported or language. We included 41 studies with 4206 participants. Time to reversal of neuromuscular blockade from second twitch to a train-of-four ratio > 0.9 was 2.0 min with sugammadex 2 mg.kg-1 and 12.9 min with neostigmine 0.05 mg.kg-1 , with a mean difference (MD) (95%CI)) of 10.2 (8.5-12.0) (I2 = 84%, 10 studies, n = 835, Grades of Recommendation, Assessment, Development and Evaluation (GRADE): moderate quality). Time to reversal of neuromuscular blockade from a post-tetanic count of 1-5 to a train-of-four ratio > 0.9 was 2.9 min with sugammadex 4 mg.kg-1 and 48.8 min with neostigmine 0.07 mg.kg-1 , with a MD (95%CI) of 45.8 (39.4-52.2) (I2 = 0%, 2 studies, n = 114, GRADE: low quality). There were significantly fewer composite adverse events in the sugammadex group compared with neostigmine, with a risk ratio (95%CI) of 0.60 (0.49-0.74) (I2 = 40%, 28 studies, n = 2298, number needed to treat (NNT): 8, GRADE: moderate quality). Specifically, the risk of bradycardia (RR (95%CI) 0.16 (0.07-0.34), n = 1218, NNT: 14, GRADE: moderate quality), postoperative nausea and vomiting (RR (95%CI) 0.52 (0.28-0.97), n = 389, NNT: 16, GRADE: low quality) and overall signs of postoperative residual paralysis (RR (95%CI) 0.40 (0.28-0.57), n = 1474, NNT: 13, GRADE: moderate quality) were all reduced. There was no significant difference regarding the risk of serious adverse events (RR 0.54, 95%CI 0.13-2.25, I2 = 0%, n = 959, GRADE: low quality). Sugammadex reverses neuromuscular blockade more rapidly than neostigmine and is associated with fewer adverse events.
引用
- Hristovska AM, Duch P, Allingstrup M, et al. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017. PMID: 29280475. doi:10.1111/anae.14160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。